Answers are grounded in this paper and cite their sources.
In this issue of Blood, Krejcik et al provide the first clinical data that describe unexpected immune stimulatory activity of the monoclonal antibody (mAb) daratumumab. By targeting CD38-expressing immune suppressive cells, clonal memory T-cell function is induced in heavily pretreated patients with relapsed and refractory multiple myeloma (MM).1
No takes yet. Share an insight, caveat, or question.
Tai et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: